Analysts See $-0.43 EPS for AnaptysBio, Inc. (ANAB); Otonomy (OTIC)’s Sentiment Is 0.93

Analysts expect AnaptysBio, Inc. (NASDAQ:ANAB) to report $-0.43 EPS on February, 6.After having $-0.45 EPS previously, AnaptysBio, Inc.’s analysts see -4.44% EPS growth. The stock decreased 3.46% or $3.82 during the last trading session, reaching $106.69. About 315,569 shares traded. AnaptysBio, Inc. (NASDAQ:ANAB) has 0.00% since January 31, 2017 and is . It has underperformed by 16.70% the S&P500.

Otonomy, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for diseases and disorders of the ear in the United States. The company has market cap of $177.47 million. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It currently has negative earnings. OTIPRIO has also completed a Phase III clinical trial for treating swimmerÂ’s ear and a Phase II clinical trial for treating acute otitis media with tubes.

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company has market cap of $2.51 billion. The companyÂ’s proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases. It currently has negative earnings. It also has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Inc. to develop and commercialize an anti-PD-1 antagonist antibody and an anti-TIM-3 antagonist antibody (TSR-022), which are under clinical development; and an inflammation partnership with Celgene Corporation to develop an anti-PD-1 checkpoint agonist antibody (CC-90006) that is in clinical stage.

New Leaf Venture Partners L.L.C. holds 0.17% of its portfolio in Otonomy, Inc. for 109,825 shares. Sio Capital Management Llc owns 100,900 shares or 0.17% of their US portfolio. Moreover, Tpg Group Holdings (Sbs) Advisors Inc. has 0.11% invested in the company for 2.16 million shares. The Georgia-based Lakeview Capital Partners Llc has invested 0.1% in the stock. Spark Investment Management Llc, a New York-based fund reported 220,000 shares.

The post Analysts See $-0.43 EPS for AnaptysBio, Inc. (ANAB); Otonomy (OTIC)’s Sentiment Is 0.93 appeared first on Stock Market News | HillCountryTimes | Get it Today.

from
https://www.hillcountrytimes.com/2018/01/31/analysts-see-0-43-eps-for-anaptysbio-inc-anab-otonomy-otics-sentiment-is-0-93/